"Not only does the Melanoscan system place a premium on the dermatologist's time, but it allows an earlier detection of melanoma resulting from evidence-based analysis. This means that we no longer have to sacrifice productivity ..."
Stamford, CT (PRWEB) October 6, 2010
The usefulness of the Melanoscan comprehensive full body digital imaging system was clinically tested using the following parameters: 1) a decision to screen pathway; 2) a clinical pathway; 3) a clinical outcome; and 4) acceptance by the patient. The system employs technicians using serial automatic whole body imaging analysis to define a set of skin lesions to undergo further analysis by a dermatologist, utilizing dermoscopy, surgery and pathology.
Preliminary results suggest that the Melanoscan change detection analysis reduces the number of biopsies and improves diagnostic accuracy. Whole body screening using the Melanoscan provides a model where accuracy of lesion tracking, patient confidence in lesion documentation, and clinician time are all optimized. "Not only does the Melanoscan system place a premium on the dermatologist's time, but it allows an earlier detection of melanoma resulting from evidence-based analysis. This means that we no longer have to sacrifice productivity in order to find the earliest, most curable melanomas" says the Melanoscan inventor, Dr. Rhett Drugge. Assessment of the survey results revealed a high degree of patient satisfaction with the ease of use and the entire screening process. The complete results of the clinical process study are described in the August 2010 edition of the "Dermatology Online Journal."
A 1999 study of store and forward teledermatology demonstrated the power of digital images and histories in conveying clinical information to the consulting dermatologist. Likewise, studies of whole body photography for melanoma screening have demonstrated the key benefit of a lowered Breslow depth upon discovery of melanoma . To date, dermatology has been hampered by a lack of access to high quality, reproducible clinical photography because of time constraints, high cost, limited availability and privacy concerns. The continued increase in the incidence of melanoma, the poor prognosis and economic burden that accompany advanced cases and the lack of a definitive, non-invasive melanoma detection technique underscore the need for an effective melanoma screening system.
Recent advances in technical methods of photography have culminated in the application of a multi-camera photo booth to whole body photography. Successful screening for melanoma requires an integrated approach, which is automated and highly reproducible from one year to the next. Since lesion change detection with whole body photography is a valuable predictor of melanoma and has been associated with improved outcomes (lower Breslow depth at discovery), combining this with effective clinical work flow management brings additional value and efficiency to the screening process. Melanomas that are discovered early and successfully treated typically have a 99%+ cure rate.
Click to learn more about melanoma risk factors. For additional information on this scientific study or for questions relating to the Melanoscan imaging system, contact Steven Scheibel or visit melanoscan.com.
Melanoscan is a medical imaging and technology company, located in Stamford, CT, putting advanced digital imaging technology to work against all forms of skin cancer.
Stamford, CT 06902